title: Desferrioxamine-related ocular toxicity: a case report.
abstract: A 29-year-old lady receiving repeated blood transfusions for β thalassemia since childhood, presented with rapidly deteriorating symptoms of night blindness and peripheral visual field loss. She was recently commenced on high-dose intravenous desferrioxamine for reducing the systemic iron overload. Clinical and investigative findings were consistent with desferrioxamine-related pigmentary retinopathy and optic neuropathy. Recovery was partial following cessation of desferrioxamine. This report highlights the ocular side-effects of desferrioxamine mesylate and the need to be vigilant in patients on high doses of desferrioxamine.
authors: Retinal Unit, Department of Ophthalmology and Visual Sciences, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, South Australia.
authors: Sumu
authors: S
authors: Simon
authors: Paul A
authors: PA
authors: Athanasiov
authors: Rajeev
authors: R
authors: Jain
authors: Grant
authors: G
authors: Raymond
authors: Jagjit S
authors: JS
authors: Gilhotra
mesh_terms: D000328:Adult; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004596:Electroretinography; D005074:Evoked Potentials, Visual; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D009901:Optic Nerve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D017262:Siderophores / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D065227:Transfusion Reaction; D017086:beta-Thalassemia / Q000628:therapy
chemical_list: D017262:Siderophores; D003676:Deferoxamine